Organon appoints Juan Camilo Arjona Ferreira as CMO

Organon announced the appointment of Juan Camilo Arjona Ferreira, M.D., as Chief Medical Officer and Charlotte Owens, M.D., as Head of Medical Affairs and Outcomes Research, strengthening the company’s global clinical and medical capabilities, advancing external relationships and fueling efforts to bring forward innovations to solve unmet health needs. Both positions report directly to Sandra Milligan, M.D., J.D., Head of Research and Development. Ferreira was CMO of Myovant Sciences Inc., and has previously held leadership roles in women’s health and other therapeutic areas at Shionogi and Merck, known as MSD outside of the United States and Canada. As the company’s CMO, Dr. Arjona Ferreira will be responsible for leading Organon’s Global Clinical Development, Clinical Trial Operations, Global Biostatistics, and Global Pharmacovigilance and Safety Science teams. He will lead strategy and execution across the company’s clinical development programs, support strong clinical engagement with regulatory authorities, and build and extend the company’s external stakeholder network around the globe. Most recently, Dr. Owens served as Vice President and Head of the Center for Health Equity & Patient Affairs at Takeda. In this role, Dr. Owens will lead medical strategy as well as support of marketed and pipeline products around the globe, including health economics and outcomes research. She will develop and foster relationships with external organizations and experts to help ensure that Organon’s products continue to meet market needs, yield desired outcomes, and enhance the organization’s reputation with providers, payers and patients.